IRWD Q3 2025 Earnings — Ironwood Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IRWDIronwood Pharmaceuticals, Inc.

$629M

Q3 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$122M+33.3% YoY

Gross Profit

$122M100.0% margin

Operating Income

$75M61.8% margin

Net Income

$40M32.8% margin

EPS (Diluted)

$0.23

QoQ Revenue Growth

+43.2%

Cash Flow

Operating Cash Flow

$48M

Free Cash Flow

$48M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$396M

Total Liabilities

$660M

Stockholders' Equity

-$264M

Cash & Equivalents

$140M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$122M	$92M	+33.3%
Gross Profit	$122M	$62M	+97.6%
Operating Income	$75M	$26M	+194.4%
Net Income	$40M	$4M	+999.3%

Revenue Segments

Royalty

$900,00064%

Collaborative arrangement, collaboration and license agreements

$423,00030%

Collaborative arrangement, other agreements

$87,0006%

Geographic Segments

North America

$120M99%

Europe and Other

$944,0001%